Looking at nearly 200 000 adults with type 2 diabetes (T2D) in the US Department of Veterans Affairs (VA) health system, a research team in Colorado identified a pattern of clinical inertia over the first 5 years after a diabetes diagnosis that included delay in initiation of second-line therapy and progressive reduction in guideline-recommended surveillance of HbA1c.
In a recent interview with Patient Care, lead study author Sridharan Raghavan, MD, PhD, discussed the ongoing shift toward decisions about choice of drug for initial or intensified treatment that are based on the presence of or risk for T2D comorbidities and complications, regardless of HbA1c.
Here, Raghavan describes a future version of his study focused on timely use of glucagon-like peptide-1 mimetics and sodium-glucose cotransporter-2 inhibitors in appropriate patients.
For more of Patient Care's conversation with Dr Raghavan, please see:
Reference: Raghavan S, Warsavage T, Liu WG, et al. Trends in timing of and glycemia at initiation of second-line type 2 diabetes treatment in US adults. Diabetes Care. Published online ahead of print March 28, 2022;dc212492.